Pay in 4 interest-free payments of $6.75 Learn more
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
Computational design of novel cyclic peptides endowed with autophagy-inhibiting activity on cancer cell lines
Select inclusion criteria include: A1C between 7.5% and 10.5% Be on at least one but no more than three of the following diabetes therapies: metformin, SGLT-2 inhibitors (Farxiga, Invokana, Jardiance, etc.), sulfonylureas (glipizide, gliclazide, etc.) Increased risk for cardiovascular (CV) events (heart attack, stroke), but have not had a CV event in the past two months
24 GLP-1, used for treating diabetes, is quickly broken down in the body, requiring high doses that can cause side effects like nausea
A test to check the medication is free of foreign organisms and pathogens
US$ 27.93
US$ 29.11
US$ 21.94
